[8-K] DiaMedica Therapeutics Inc. Reports Material Event

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Analyzing...

07/17/2025 - 08:05 AM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Diamedica Therapeutics Inc

NASDAQ:DMAC

DMAC Rankings

#5530 Ranked by Market Cap

N/A Ranked by Dividends

DMAC Latest News

Jul 17, 2025

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

Jun 24, 2025

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

May 22, 2025

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

May 19, 2025

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

May 14, 2025

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

DMAC Stock Data

Market Cap 157.38M

Float 26.09M

Insiders Ownership 26.12%

Institutions Ownership 34.19%

Short Percent 0.59%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City MINNEAPOLIS